Navigation Links
Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc.
Date:7/14/2011

AVENTURA, Fla., July 14, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DEGH), the parent company of Fuse Science, Inc. (www.fusescience.com), announced today that it has entered into a research and development agreement with Platform Delivery Technologies Inc. (PDT Inc.), a California-based pharmaceutical consulting firm. Double Eagle Holdings is the parent company of Fuse Science, Inc., the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.

The team at PDT Inc. has been responsible for numerous product formulations currently on the market, including line extensions for Chloraseptic, private label electrolyte replacement formulas for national drugstore chains, Zicam Cold formulas and several prescription pharmaceuticals. The PDT Inc. team has more than 30 pending and issued patents in the pharmaceutical and sports performance industries.

"PDT Inc. has provided exclusive formulations and proprietary branding for many of the world's top pharmaceutical companies. Through this agreement, our ability to bridge into several major product categories is a certainty," said Brian Tuffin, Fuse Science President and Chief Operating Officer. "Our strong working relationship will accelerate our commercialization efforts."

Under the terms of the agreement, PDT Inc. will oversee a team of scientists facilitating the formulation and manufacturing of several Fuse Science products that leverage the Company's industry-leading Fusome Technology. The team's focus will be ongoing product innovation while working to advance Fuse Science's technology, intellectual property and patents. Rob Davidson, the team's managing director, reported today that PDT Inc. has already completed work on three new industry standards and proprietary formulations as Fuse Science prepares to enter the sports nutrition and performance categories. These are:

  • EnerJel – For active muscle fatigue, a real time anti-inflammatory and energy source applied directly to the problem area to help athletes finish the game
  • PowerDrops – Concentrated electrolyte delivery in a single drop before the game for stronger, sustained performance
  • EnergyDrops – An all-natural, faster-acting energy source with longer-lasting results in a single drop

"It is our firm belief that through the Fuse Science formulary technology, we can deliver user benefits faster and more effectively than typical sports drinks, pills and gels that are currently available on the market," added Dr. Edward Maliski, PDT Inc.'s Director of Research and Development.

Fuse Science products will be manufactured in full compliance with current good manufacturing practices (cGMP) set forth by the U.S. Food and Drug Administration, and as the company advances into larger categories, it intends to further maintain strict adherence to all FDA and regulatory compliance standards. In addition, because one of the natural markets for Fuse Science products is in the athletic and fitness space, extreme care has been taken to ensure that all of the company's products are in compliance with the banned substances policies of the world's major sports leagues.

Davidson's PDT Inc. team includes Dr. Maliski and Dr. Eric E. Allen. Dr. Maliski is an accomplished research scientist with 30 years' experience in the development of pharmaceutical and biotechnology products, and whose background includes work for the Sterling Winthrop Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc. A recognized authority in the pharmaceutical industry for his work in drug discovery, Dr. Allen is an inventor on 16 drug-related, issued U.S. patents and brings nearly 25 years of pharmaceutical industry experience, including 10 years at Merck & Co.

"This is another key step in the journey to significant shareholder value," added Tuffin. "We have a tremendous science platform to build on, and this partnership will enhance our efforts. In the coming days and weeks we will begin to announce further strategic partnerships and endorsements from several of America's most notable athletes."

About Double Eagle Holdings

Double Eagle Holdings (OTCQB: DEGH) is an innovative consumer products holding company and the parent company of Fuse Science, Inc. Based in Aventura, Florida, Fuse Science is the developer of patent-pending conveyance technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, delivering their benefits faster and more effectively than ever before. Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the company's SEC filings. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.


'/>"/>
SOURCE Double Eagle Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
4. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
7. Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby
8. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
11. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really works. ... be incorporated into the post-surgical treatment plans of a variety of other procedures including, ... is very effective for bruising and causes a rapid resolution of bruising and inflammatory ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Dr. Seema ... joins Evans Dermatology in the South Lamar location as of July 13, 2016. , ... Medical School. As a medical student, she regularly volunteered at the Agape Clinic serving ...
Breaking Medicine News(10 mins):